相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence and risk factors of Helicobacter pylori infection in Korea: Nationwide multicenter study over 13 years
Seon Hee Lim et al.
BMC GASTROENTEROLOGY (2013)
Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials
Hui-Lin Tang et al.
PLOS ONE (2013)
Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection
A. G. McNicholl et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report
Peter Malfertheiner et al.
GUT (2012)
The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole
Jeong Hoon Lee et al.
GUT AND LIVER (2010)
Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition
Masahiro Asaka et al.
HELICOBACTER (2010)
Helicobacter pylori Infection
Kenneth E. L. McColl
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy of Helicobacter pylori eradication therapy in chronic liver disease
S. W. Jung et al.
DIGESTIVE AND LIVER DISEASE (2009)
Annual Change of Primary Resistance to Clarithromycin among Helicobacter pylori Isolates from 1996 through 2008 in Japan
Noriyuki Horiki et al.
HELICOBACTER (2009)
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection
K. Ming Fock et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis
Fujun Zhao et al.
HELICOBACTER (2008)
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage
Jung Mook Kang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
Rabeprazole- versus esomeprazole-based eradication regimens for H-Pylori infection
I-Chen Wu et al.
HELICOBACTER (2007)
American college of gastroenterology guideline on the management of Helicobacter pylori infection
William D. Chey et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease and its relation to pulmonary function tests
Mehmet Gencer et al.
RESPIRATION (2007)
Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea
Nayoung Kim et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2006)
Systematic review and meta-analysis:: importance of CagA status for successful eradication of Helicobacter pylori infection
T. Suzuki et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
The effect of CYP2C19 polymorphisms on H-Pylori eradication rate in dual and triple first-line PPI therapies:: A meta-analysis
Sara Padol et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients
Jung Mogg Kim et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients
JM Kim et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication
PI Hsu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Helicobacter pyloriinfection in hemodialysis patients: Susceptibility to amoxicillin and clarithromycin
Selim Aydemir et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545 adults
J Kuepper-Nybelen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea
JM Kim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States
WM Duck et al.
EMERGING INFECTIOUS DISEASES (2004)
Second-line treatment for failure to eradicate Helicobacter pylori:: a randomized trial comparing four treatment strategies
H Lamouliatte et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Pharmacogenetics of the proton pump inhibitors: A systematic review
E Chong et al.
PHARMACOTHERAPY (2003)
Alterations in penicillin-binding protein 1A confer resistance to β-lactam antibiotics in Helicobacter pylori
MM Gerrits et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Current concepts in the management of Helicobacter pylori infection -: The Maastricht 2-2000 Consensus Report
P Malfertheiner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H-pylori antimicrobial resistance partnership (SHARP) study, 1993-1999
JM Meyer et al.
ANNALS OF INTERNAL MEDICINE (2002)
European Multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori
Y Glupczynski et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2001)
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'
F Perri et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea
JJ Kim et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Helicobacter pylori infection and coronary heart disease in Japanese patients
H Osawa et al.
CARDIOLOGY (2001)
分享论文
